Press release UK and Singapore launch a regulatory innovation corridor to speed up access to breakthrough health technologies : 12 December 2025
Patients in the UK and Singapore could gain faster access to cutting-edge healthcare innovations under a new partnership bringing two globally respected regulators together with one of the world’s leading biotech creators.
Patients in the UK and Singapore could benefit sooner from major medical advances as the UK and Singapore launch a new regulatory innovation corridor to fast-track the most promising healthcare innovations today (12 December).
As part of this first-of-its-kind regulatory collaboration, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore’s Health Sciences Authority (HSA), with Flagship Pioneering as its first partner, companies will have a coordinated pathway enabling them to engage with both regulators at the same time. Under the new corridor, developers will be able to seek early, informal joint advice, helping them plan ahead and design better clinical trials, avoid duplication and cut delays.
The aim is to speed up patient access to breakthrough therapies in high-impact areas such as cancer, neurodegenerative disease, obesity, rare diseases and advanced diagnostics – without compromising on safety. The partnership will help both countries horizon scan for emerging technologies and therapeutic modalities, learn from each other’s regulatory approaches and boost regulatory innovation, strengthening their position as global hubs for life science investment.
Flagship Pioneering, a scientific innovation engine that generates transformative platforms and products, will be the first company to access the new Regulatory Innovation Corridor, due to its strategic commitment with both countries. Its early-stage programmes across an ecosystem of more than 40 companies span a broad range of new therapeutic modalities that could inform regulatory paradigm shifts on the horizon. This includes next-generation genetic medicines, precision immunology and digital health, providing both countries visibility into a strong pipeline of potential breakthroughs to prepare to assess safely and innovatively.
Health Innovation Minister Dr Zubir Ahmed, said: “This partnership is exactly the kind of innovation we need to deliver on our mission to build an NHS fit for the future. Working with Singapore to fast-track breakthrough treatments in areas like cancer, dementia and rare diseases means NHS patients could get faster access to life-changing therapies.
“By enabling companies to work with both regulators at once, we’re also making the UK more attractive for life sciences investment and securing the high-skilled jobs and research that comes with it. That’s good for patients and good for the economy.”
UK Science Minister Lord Patrick Vallance, said: “Singapore is renowned for its excellence in medical research and innovation, and already has strong ties with the UK. By working together, we can streamline regulatory processes and remove unnecessary barriers, making it easier for researchers to run clinical trials in both our countries.
“That means more investment, more cutting-edge research, and ultimately faster access to new medicines for patients, with the added benefit of ensuring the UK remains at the forefront of global health innovation.”
The partnership builds on a long track record of UK–Singapore cooperation in science and technology. Together, the MHRA and HSA will work more closely on early diagnosis, prevention, healthy ageing and digital health, supporting national strategies in both countries – including England’s 10-Year Health Plan and Singapore’s Ministry of Health Healthier SG programme.
The collaboration will be supported by joint work on AI in healthcare, with both regulators acting as the first two pioneer countries in the HealthAI Global Regulatory Network, and also draw on the UK’s National Commission into the Regulation of AI in Healthcare. HSA Chief Executive Adjunct Professor (Dr) Raymond Chua has recently joined the National Commission as a member, bringing Singapore’s regulatory expertise to help develop the new framework for AI in healthcare.
This new route forms part of wider efforts to unlock growth in UK life sciences and make simpler for global innovators to bring safe, effective medicines and medical technologies to patients. Recent MHRA initiatives include its AI Airlock – a regulatory sandbox for AI medical devices – which lets companies test new tools with the regulator before wider NHS roll-out; the Innovative Licensing and Access Pathway (ILAP) which streamlines development in areas of urgent unmet need; and its Centres of Excellence for Regulatory Science and Innovation (CERSIs) working directly with researchers to navigate complex science. Together, these changes are designed to streamline development, support investment and provide clearer routes for companies working at the cutting edge of science.
This partnership on the new route also builds on HSA’s ongoing efforts to strengthen Singapore’s position as a leading biotech hub, accelerate access to innovative health technologies, and set the pace in global regulatory innovation. HSA’s recent initiatives also include ASCENT1 – the Centre for Advancing Regulatory Science Research in Next-Generation Therapeutics – a partnership between HSA and A*STAR (Agency for Science, Technology and Research) that will strengthen Singapore’s position as a global thought leader in evaluating and approving novel biotherapeutics and digital technologies; and the review of the AI in Healthcare Guidelines (AIHGle), published by the Ministry of Health, HSA and national healthtech agency Synapxe, which provides practical guidance for the safe and effective use of AI across Singapore’s healthcare ecosystem. These guidelines are periodically updated to keep pace with emerging AI technologies.
Lawrence Tallon, Chief Executive of the MHRA, said: “This new fast-track route marks a significant shift in how trusted regulators can work together. By bringing together the UK’s research strength with Singapore’s agile approach to emerging technologies – and working early with companies like Flagship Pioneering – we can help companies build better evidence from the start and avoid delays in development.
“For patients in the UK, this means earlier access to promising treatments in areas where progress is urgently needed. Safety remains at the heart of our mission, and this partnership strengthens our ability to assess fast-moving science while maintaining the high standards the public expects.
“This approach also supports the wider UK life sciences economy. A clearer, more predictable path to market helps attract global investment, gives innovators confidence to develop their products here, and strengthens the UK’s position as a leading hub for the next generation of medicines and medical technologies.”
Adjunct Professor (Dr) Raymond Chua, Chief Executive Officer of the Health Sciences Authority, said: “The Regulatory Innovation Corridor marks a significant milestone in how two regulators, Singapore’s HSA and the UK’s MHRA, can come together to advance global regulatory innovation and benefit patients.
“Building on our strong collaborative work through the Access Consortium, both HSA and MHRA will co-create transparent, science-based approaches to assess breakthrough technologies. And we are indeed glad to have Flagship Pioneering as the first company accessing this new corridor, which will foster shared learning between all parties, and future partners, to enable more forward-looking pathways to move breakthrough ideas in key priority areas from lab to market.
“This partnership advances our shared commitment to regulatory science and excellence, and to support Singapore’s latest research priorities, enabling faster, smarter pathways for innovation while maintaining public trust and patient safety.”
Noubar Afeyan, Ph. D., Founder and CEO of Flagship Pioneering, said: “Global challenges in human health demand global regulatory innovation. By establishing this corridor, the UK and Singapore are signalling a shared commitment to accelerating breakthrough science responsibly and at scale. Through this partnership, Flagship Pioneering and our companies can engage earlier and more efficiently with two highly respected regulators, helping us advance transformative technologies that have the potential to redefine patient care. We view this as a model for how forward-looking nations can work with innovators to unlock faster, safer paths to patient impact.” https://gov.uk/government/news/uk-and-singapore-launch-a-regulatory-innovation-corridor-to-speed-up-access-to-breakthrough-health-technologies
EU legislators reach agreement on landmark pharmaceutical package : 11 December 2025
The European Commission, the European Parliament, and the Council of the European Union have agreed on a significant reform of the EU’s pharmaceutical legislation. If the proposed legislation is adopted, it will reportedly simplify the drug regulatory regime within the economic zone, promote innovation, and secure the drug supply chain, according to EU officials.
On 11 December, the EU Parliament reached a provisional agreement with the other EU bodies to update Europe's drug policy framework. A key aspect of the agreement is to simplify the EU drug regulatory environment by reducing the European Medicines Agency's (EMA) human drugs committee structure from five scientific committees to two. The remaining two committees will be the Committee for Human Medicinal Products (CHMP) and the Pharmacovigilance Risk Assessment Committee (PRAC).
"Today marks a historic milestone for European medicines regulation and for patients across the EU," said EMA Executive Director Emer Cooke. "The revamp of the pharmaceutical legislation will enable EMA and the European medicines regulatory agencies network to become more agile and efficient while upholding the highest standards of scientific rigor.
"By simplifying procedures, embracing digitalization and rationalizing our use of scientific resources, we will be better positioned to support innovation and ensure that promising new treatments reach patients faster," she added. "The new legislation also provides us with the tools to deliver on our network strategy to 2028 and address the major public health challenges of the future, from antimicrobial resistance to emerging health threats."
The regulatory changes would mean that EMA will review drug marketing applications within 180 days instead of the current 210 days, which the agency said will free up scientific resources and allow it to provide drug developers with more pre-authorization support. Furthermore, it stated that the reform will mean that marketing authorization will be granted by default for an unlimited period, thereby eliminating the need for marketing authorization holders (MAHs) to renew their applications unless a safety concern arises.
The EU Parliament also noted that the proposed legislation would give MAHs regulatory data protection for eight years. During that time, other companies would not be able to access data on the authorized product, and an additional year of market protection. Drugmakers would also be eligible for an extra year of marketing protection for their drug if certain conditions are met, such as if the drug addresses an unmet need, up to 11 years of combined regulatory protection. EMA stated that the reform would require drug applicants to submit their applications in electronic and structured formats, and that product information must be available in electronic form (ePI).
In addition to the regulatory reforms, European legislators and regulators stated that the updated pharmaceutical legislation will enhance drug innovation by enabling EMA to provide extended scientific advice to drug developers in collaboration with health technology assessment (HTA) bodies and medical device expert panels. EMA said it also suggested that the Commission establish a "regulatory sandbox" as part of the legislation to test and develop adapted regulatory requirements, allowing the development of new drugs that can't be developed under current rules.
The legislation would also create adapted frameworks for certain non-standard treatments, such as personalized medicines, and improve the pediatric investigation plan (PIPs) process, which the EMA is evaluating as part of a pilot.
The proposed legislation is also intended to strengthen the drug supply chain by introducing several new rules, including establishing new drug shortage reporting requirements for manufacturers and creating a European list of critical medicines that require monitoring, as well as enhancing the EU's capacity to address antimicrobial resistance (AMR).
“Companies holding marketing authorizations for medicinal products would be required to put in place and update shortage prevention plans for medicinal products subject to prescription and medicinal products that would require a shortage prevention plan identified by the Commission,” said the EU Parliament. “Shortages would be monitored at both national and EU levels, and the EMA would establish and update a list of critical shortages in the EU.
“Negotiators agreed to introduce a ‘transferable data exclusivity voucher’ for priority antimicrobials, giving the right to 12 additional months of data protection for one authorized product,” the Parliament added. “The 12-month extension may be used once, for the priority antimicrobial or for another centrally authorized medicinal product of the same or different marketing authorization holder.”
The proposed legislative reforms will need to be approved by the EU Parliament and the Council; however, there is no specific timeline for when that will happen.
"Over the coming months and years, once the text has been formally approved, EMA will work together with the European Commission and EU Member States, to develop relevant guidance for applicants and marketing authorisation holders to comply with the new legal framework," said EMA. "To ensure the smooth implementation of the legislation, EMA’s stakeholders will be kept informed and actively involved in the implementation process on specific technical and procedural aspects of the reform.
"EMA plans to publish a new web page that will serve as a gateway and central repository of information on implementation of the new legislation for EMA’s stakeholders," the agency added. "The webpage will be updated as implementation work progresses and guidance for pharmaceutical companies becomes available." The lobby group, European Federation of Pharmaceutical Industries and Associations (EFPIA), argued that while the proposed legislation marks a significant moment in shaping the future of the drug industry in the EU, it is not strong enough to boost competitiveness in the region. The group said the legislation maintains eight years of regulatory data protection, which is an improvement on the Commission's previous proposal, and argued that certain compromises in the legislation will frustrate intellectual property enforcement and create legal uncertainty.
"These compromises are from a previous political era and will make no difference for a sector already losing ground," said EFPIA. "To compete in 2026 and beyond, Europe requires policies that can halt the negative trends of previous years while also countering the fallout of recent global pricing and trade policies, ensuring that we can continue to lead global innovation in medicines and vaccines.
"In this sense, the updating of the EU’s regulatory framework provides an important shift, with encouraging steps towards reducing EMA timelines and the ability to compete with the FDA and other global medicines agencies," the group added. "The introduction of a regulatory sandbox strengthens Europe’s toolbox for supporting breakthrough innovations. We support the long-awaited transition to electronic product information, bringing essential flexibility and aligning regulation with technological progress."
The rare disease advocacy group EURODIS, however, was more optimistic about the deal, stating that it was a momentous advancement for people with rare diseases.
"By establishing modulated incentives for all medicines, as well as for orphan drugs – including through the new ‘breakthrough orphan medicinal products’ category, which grants longer market exclusivity for certain new therapies – Europe has created the conditions to stimulate innovation, including for the rarest and most complex conditions. The package also delivers practical reforms, including shortened EMA timelines and strengthened supply safeguards, that should speed up approvals and help ensure medicines reach patients," said EURODIS President Avril Daly. “Wisely, the agreement also allows the Commission to enable more adaptable pathways, including by creating regulatory sandboxes under strict conditions – a pragmatic route to test innovative therapies."
Market Data 
Markets 
